EVALUATION OF THE CLINICAL EFFICACY OF A VITAMIN-AND-MINERAL COMPLEX FOR THE PREVENTION OF PREGNANCY COMPLICATIONS

Objective. To evaluate the efficacy of elevit pronatal in the prevention of iron-deficiency anemia (IDA) and gestosis during pregnancy. Subjects and methods. The study enrolled 60 pregnant women treated in the first trimester for threatening miscarriage or for the need for invasive prenatal diagnosis at the Antenatal Department, D. O. Ott Research Institute of Obstetrics and Gynecology. These women were later observed in the first, second, and third trimesters of pregnancy. Their clinical and laboratory examination (before and 1 month after the use of the test drug) included clinical and biochemical (serum iron, ferritin, transferrin, homocysteine, total protein, and the electrolytes Ca, K, Na, Mg) blood analyses and determination of blood total antioxidative and total antiradical activities (AOA and ARA). The course of pregnancy and labor outcomes were estimated. Results. Prior to the use of elevit prenatal, the first trimester was marked by the enhanced total AOA that was 0.795±0.051 relative units. With the drug use, the patients showed a significant increase in serum iron levels within the physiological range; there was normalization of total AOA up to 0.731±0.043 relative units (p > 0.05). Before start of therapy, serum total ARA was in the lower normal range, which was 783.0±31.6 μmole. In the third trimester, 3 (5.5%) patients with multiple pregnancy were found to have gestosis that was mild (up to 7 scores). The rate of gestosis was much lower than the average population one (25-30%) in Russia. Conclusion. In the second trimester of pregnancy, the use of elevit pronatal enhanced ARA up to 870.3±37.0 μmole. There was a significant, more than 2-fold, reduction in blood homocysteine levels from 9.4±2.1 to 4.6±0.8 μmol/l (p<0.05). Gestosis was not a cause of preterm or surgical delivery in any of the examinees.

vitamin-and-mineral complex, prevention, anemia, endothelial dysfunction, gestosis